» Articles » PMID: 38298045

Potency Classification of Isothiazolinone Compounds Based on Defined Approaches of Skin Sensitization in OECD GL 497

Overview
Date 2024 Feb 1
PMID 38298045
Authors
Affiliations
Soon will be listed here.
Abstract

Regulatory decisions for skin sensitization are now based on adverse outcome pathway (AOP) and integrated approaches to testing and assessment (IATA). Based on these, Organisation for Economic Co-operation and Development (OECD) guidelines on defined approaches for skin sensitization were adopted with a fixed data interpretation procedure (DIP). In the guidelines, "Defined Approaches" (DA) on skin sensitization uses the results from multiple information sources of in chemico, in vitro, and in silico data to achieve an equivalent predictive capacity as those of the animal tests. In this review, we evaluated the skin sensitization of eleven isothiazolinone compounds including 4,5-Dichloro-2-octyl-3(2H)-isothiazolone (DCOIT), 2-n-Octyl-4-isothiazolin-3-one (OIT), 2-Methyl-4-isothiazolin-3-one (MIT), 1,2-Benzisothiazolin-3-one (BIT), 1,2-Benzisothiazolin-3-one, 2-butyl (BBIT), 5-Chloro-2-methyl-4-isothiazolin-3-one (CMIT), 2-methyl-4,5-trimethylene-4-isothiazolin-3-one (MTMIT), 2-methyl-1,2-benzothiazol-3-one (MBIT), 2-methyl-1,2-benzothiazole-3-thione (MBIT-S), 1,2-benzisothiazolin-3-one, 2-methyl-, 1,1-dioxide (BBIT-O), and a mixture of CMIT/MIT. Data from direct peptide reactivity assay (DPRA), human cell line activation (h-CLAT) test, and quantitative structure activity relationship (QSAR) Toolbox were evaluated and were applied to the DIP to derive a prediction of hazard identification and a potency classification. Among the evaluated chemicals, six isothiazolinone compounds were classified to be UN GHS 1A, one compound to be UN GHS 1, and four compounds could not be classified due to lack of data. The results of sensitizer chemicals were found to coincide well with those of in vivo test.

References
1.
Li H, Bai J, Zhong G, Lin H, He C, Dai R . Improved defined approaches for predicting skin sensitization hazard and potency in humans. ALTEX. 2019; 36(3):363-372. DOI: 10.14573/altex.1809191. View

2.
Coady K, Browne P, Embry M, Hill T, Leinala E, Steeger T . When Are Adverse Outcome Pathways and Associated Assays "Fit for Purpose" for Regulatory Decision-Making and Management of Chemicals?. Integr Environ Assess Manag. 2019; 15(4):633-647. PMC: 6771501. DOI: 10.1002/ieam.4153. View

3.
Strickland J, Allen D, Germolec D, Kleinstreuer N, Johnson V, Gulledge T . Application of Defined Approaches to Assess Skin Sensitization Potency of Isothiazolinone Compounds. Appl In Vitro Toxicol. 2023; 8(4):117-128. PMC: 9814110. DOI: 10.1089/aivt.2022.0014. View

4.
Casati S . Integrated Approaches to Testing and Assessment. Basic Clin Pharmacol Toxicol. 2018; 123 Suppl 5:51-55. DOI: 10.1111/bcpt.13018. View

5.
Sakuratani Y, Horie M, Leinala E . Integrated Approaches to Testing and Assessment: OECD Activities on the Development and Use of Adverse Outcome Pathways and Case Studies. Basic Clin Pharmacol Toxicol. 2018; 123 Suppl 5:20-28. DOI: 10.1111/bcpt.12955. View